Open AccessThe Clinical Aspects of Saroglitazar and its Side Effects
Author(s) -
Vadlamudi Naga Ratna Sai,
Sreenivas Pasula,
Sheelam Sumathi,
Mondra Sreekanth,
A. Srinivas Rao,
Beda Durga Prasad
Publication year - 2020
Publication title -
journal of drug delivery and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2250-1177
DOI - 10.22270/jddt.v10i2.3941
Subject(s) - glycemic , medicine , drug , diabetes mellitus , hypertriglyceridemia , pharmacology , cholesterol , endocrinology , triglyceride
The new substance element has been known as novel antidiabetic drug, eg: saroglitazar. saroglitazar is a medication used to treat type-2 diabetes. saroglitazar was known under the exchange name Lipaglyn, created by Zydus cadila. lipaglyn is the first drug approved to treat type-2diabetes mellitus by the drug controller general of India in june 2013. Lipaglyn is demonstrated for the patients experiencing diabetes dyslipidaemia. It is given once daily for treatment. Saroglitazar manages the lipid parameters just as glycemic control. [1]
Keywords: Anti-diabetic, dual PPAR agonist, glitazar, hypertriglyceridemia, insulin sensitizer, Lipaglyn, AE’s (adverse effects).